- Home
- GUTS
GUTS
FRACTYL HEALTH INC
as 05-20-2024 4:00pm EST
$.
-
$.
-.%
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | BURLINGTON |
| Market Cap: | 338.2M | IPO Year: | 2024 |
| Target Price: | $18.00 | AVG Volume (30 days): | 302.9K |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.43 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.75 - $14.50 | Next Earning Date: | 05-13-2024 |
| Revenue: | $148,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Share on Social Networks:
Stock Insider Trading Activity of FRACTYL HEALTH INC (GUTS)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Royan Ajay | GUTS | Director10% Owner | Feb 6 '24 | Buy | $15.00 | 333,333 | $4,999,995.00 | 1,251,900 | SEC Form 4 |
| Elia Marc | GUTS | Director | Feb 6 '24 | Buy | $15.00 | 466,666 | $6,999,990.00 | 1,856,117 | SEC Form 4 |
| Mithril LP | GUTS | 10% Owner | Feb 6 '24 | Buy | $15.00 | 333,333 | $4,999,995.00 | 1,251,900 | SEC Form 4 |
| CVF, LLC | GUTS | 10% Owner | Feb 6 '24 | Buy | $15.00 | 333,333 | $4,999,995.00 | 4,673,870 | SEC Form 4 |
Latest FRACTYL HEALTH INC News
GUTS Breaking Stock News: Dive into GUTS Ticker-Specific Updates for Smart Investing
GlobeNewswire
10 hours ago
Fractyl Health Presents Compelling Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva® at Digestive Disease Week 2024
GlobeNewswire
7 days ago
Fractyl Health Reports First Quarter 2024 Financial Results and Provides Business Updates
MT Newswires
7 days ago
Fractyl Health Says New Revita Data Show Sustained Weight Loss, Glucose Control in Type 2 Diabetes
GlobeNewswire
7 days ago
Fractyl Health Presents Clinical Update on Revita® German Real-World Registry for Patients With Advanced Type 2 Diabetes (T2D)
GlobeNewswire
12 days ago
Fractyl Health to Present at BofA Securities 2024 Health Care Conference
GlobeNewswire
13 days ago
Fractyl Health to Report First Quarter 2024 Financial Results and Provide Business Updates on May 13, 2024
Simply Wall St.
17 days ago
Fractyl Health, Inc.'s (NASDAQ:GUTS) largest shareholders are private equity firms with 52% ownership, individual investors own 30%
GlobeNewswire
20 days ago